Our Pricing

Switching From Ozempic to Wegovy or Mounjaro: UK Clinical Guidance

Published on: June 03, 2026

Considering whether to switch from Ozempic to Wegovy or Mounjaro UK? Many patients transition between GLP-1 receptor agonists to optimise weight loss outcomes, and at Cured Pharmacy, our UK-registered prescribers provide expert guidance on safe medication transitions. Understanding the clinical differences, switching protocols, and expected outcomes helps you make an informed decision with professional support.

Why Patients Switch From Ozempic to Alternative GLP-1 Medications

Ozempic (semaglutide) was originally licensed by the MHRA for type 2 diabetes management, though it's frequently prescribed off-label for weight loss in the UK. Patients often consider switching to Wegovy or Mounjaro because these medications are specifically licensed for weight management and may offer enhanced efficacy [1].

Clinical trials demonstrate that Mounjaro (tirzepatide) produces superior weight loss outcomes compared to semaglutide-based treatments. In the SURPASS-2 head-to-head trial, tirzepatide achieved up to 15.7% average body weight reduction versus 5.7% with semaglutide 1mg over 40 weeks [2]. Wegovy, which contains the same active ingredient as Ozempic but at higher therapeutic doses (up to 2.4mg), showed average weight loss of 14.9% in the STEP 1 trial [3].

Common reasons for switching include inadequate weight loss progress on current therapy, supply chain considerations, cost factors, or a prescriber's recommendation to optimise treatment outcomes. Your UK prescriber will assess whether transitioning aligns with your clinical profile and weight management goals.

Switching From Ozempic to Mounjaro: Clinical Protocol

Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist that works through two complementary pathways rather than semaglutide's single mechanism. This dual action contributes to the enhanced weight loss observed in clinical trials [2][4].

When transitioning from Ozempic to Mounjaro, UK prescribers typically recommend starting with the lowest Mounjaro dose (2.5mg weekly) regardless of your previous Ozempic dose. This approach minimises gastrointestinal side effects whilst your body adjusts to the new medication's dual-receptor mechanism. You can begin Mounjaro the week after your last Ozempic injection, as both medications have similar weekly dosing schedules.

The standard Mounjaro titration follows a structured escalation: 2.5mg for four weeks, then 5mg for four weeks, with potential increases to 7.5mg, 10mg, 12.5mg, or 15mg based on tolerability and clinical response. Your prescriber will monitor your progress and adjust the dose accordingly. Mounjaro is available at Cured Pharmacy from £124.99 with pricing determined by your prescribed maintenance dose following clinical assessment.

Expected Timeline and Outcomes

Most patients tolerate the transition well, though mild gastrointestinal symptoms (nausea, reduced appetite) may occur during the first 4-8 weeks as your body adapts. These effects typically diminish with continued use. Weight loss acceleration often becomes apparent after reaching therapeutic doses, generally within 12-16 weeks of initiating Mounjaro therapy [4].

Switching From Ozempic to Wegovy: What You Need to Know

Wegovy and Ozempic both contain semaglutide, but Wegovy is licensed specifically for chronic weight management at higher doses (up to 2.4mg weekly) compared to Ozempic's diabetes-focused dosing (up to 1mg weekly). If you've been using Ozempic off-label for weight loss, switching to Wegovy provides access to the higher therapeutic doses proven in weight management trials [3].

The transition from Ozempic to Wegovy requires careful dose mapping by your UK prescriber. If you're currently on Ozempic 1mg weekly, you might transition directly to Wegovy 1.7mg or 2.4mg, depending on your tolerability and clinical assessment. Alternatively, your prescriber may recommend a gradual escalation through Wegovy's standard titration schedule to minimise side effects.

Because both medications contain the same active ingredient, the switching process is generally straightforward. You can start Wegovy the week after your last Ozempic dose, maintaining the once-weekly injection schedule. Wegovy is available at Cured Pharmacy from £20 off first order using code WEIGHTLOSSNEW

Dose Equivalency Considerations

Clinical equivalency between Ozempic and Wegovy doses isn't always one-to-one. Your prescriber will evaluate your current response, any side effects, and weight loss trajectory to determine the most appropriate Wegovy starting dose. The goal is to reach the therapeutic 2.4mg dose where maximum efficacy was demonstrated in clinical trials, whilst ensuring tolerability throughout the transition [3].

Comparing Mounjaro and Wegovy: Which Offers Better Results?

Head-to-head clinical data provides valuable insight for patients deciding between these two leading weight loss medications. In the SURPASS-2 trial, tirzepatide (Mounjaro) demonstrated superior weight loss compared to semaglutide at equivalent therapeutic doses, with the highest tirzepatide dose achieving nearly three times the weight reduction of semaglutide 1mg [2].

Wegovy's STEP trial programme showed impressive results with average weight loss of 14.9% over 68 weeks at the 2.4mg dose [3]. Mounjaro's SURMOUNT-1 trial reported even higher outcomes, with average weight loss reaching 20.9% at the 15mg dose over 72 weeks [4]. Both medications require long-term commitment and lifestyle modifications including dietary changes and increased physical activity.

Individual response varies considerably, and some patients may experience better tolerability or outcomes with one medication over the other. Factors your UK prescriber will consider include your medical history, previous medication responses, concurrent health conditions, and personal preferences regarding injection frequency and side effect profiles. Both medications are administered as once-weekly subcutaneous injections.

Side Effect Profiles

Gastrointestinal side effects (nausea, diarrhoea, constipation, vomiting) are common with both medications, particularly during dose escalation. Clinical trial data suggests similar tolerability profiles, though tirzepatide's dual-receptor mechanism may produce slightly different symptom patterns in some patients [2][4]. Your prescriber can recommend strategies to minimise these effects, including slower titration schedules and dietary adjustments.

Safety Considerations When Switching Weight Loss Medications

All GLP-1 receptor agonists carry similar contraindications and precautions. You should not switch to Wegovy or Mounjaro if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. These medications are also contraindicated in pregnancy, and effective contraception is essential for women of childbearing potential [1][3][4].

Before switching, your UK prescriber will review your complete medical history, including any diabetic retinopathy, pancreatitis history, kidney function, and concurrent medications. If you experienced significant side effects on Ozempic, this information helps determine whether an alternative GLP-1 medication is appropriate or whether a slower titration schedule might improve tolerability.

Regular monitoring is essential after switching. Your prescriber may recommend follow-up consultations to assess your response, adjust dosing, and address any concerns. At Cured Pharmacy, our UK-registered clinical team provides ongoing support throughout your weight management journey, ensuring safe and effective treatment under proper medical supervision.

How to Switch From Ozempic at Cured Pharmacy

Transitioning your weight loss medication through Cured Pharmacy is straightforward and fully compliant with UK regulations. Begin by completing our free online clinical assessment, which takes under three minutes. You'll provide information about your current Ozempic therapy, weight loss progress, any side effects, and your medical history.

A UK-registered prescriber from our clinical team will review your assessment, typically within 24 hours. If switching to Mounjaro or Wegovy is clinically appropriate, they'll determine your starting dose and provide detailed instructions for the transition. Your medication is then dispensed by our GPhC-registered pharmacy (registration number 9012511) and delivered in discreet packaging to your UK address.

Our transparent pricing means you'll see exact costs before completing your consultation. Mounjaro is available from £124.99 and Wegovy from £135.00 with final pricing based on your prescribed dose. We guarantee the lowest prices in the UK for genuine, MHRA-licensed medications. If you have questions during your transition, our pharmacy team is available on (+44) 116 4646009 to provide expert guidance under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg solution for injection in pre-filled pen. GOV.UK. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
2. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1): A Randomised, Double-Blind, Placebo-Controlled Trial. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet, 400(10350), 563–571. https://doi.org/10.1016/S0140-6736(22)00941-3 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication or switching between treatments. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to therapy and lifestyle modifications.